National Cancer Institute (NCI): all 3,554 studies

Page 23 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsActive, not recruitingNCT01362803Phase 1/2
• Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone MetabolismCompletedNCT01361165
• Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid TumorsCompletedNCT01352962Phase 1
• Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01351909Phase 1
• Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center ProgramsCompletedNCT01346280
• MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT01344031Phase 1
• Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalTerminatedNCT01341496Phase 1
• Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, ChinaCompletedNCT01338285
• Dose-Finding of Retinoid 9cUAB30 in Healthy VolunteersTerminatedNCT01336387Phase 1
• Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaCompletedNCT01330173Phase 1
• Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT01327781Phase 1
• AZD8055 for Adults With Recurrent GliomasCompletedNCT01316809Phase 1
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or MelanomaActive, not recruitingNCT01303341Phase 1
• Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate CancerCompletedNCT01296139Phase 1
• AZD6244 With Cetuximab for Solid Tumors and Colorectal CancerCompletedNCT01287130Phase 1
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• Message Testing for Tobacco-Related Corrective StatementsCompletedNCT01282008
• (11C)dLop as a Marker of P-Glycoprotein Function in Patients With GliomasTerminatedNCT01281982
• Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical CancerCompletedNCT01281852Phase 1
• High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT01281176Phase 1
• Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerTerminatedNCT01281163Phase 1
• Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT01281150Phase 1
• Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryCompletedNCT01276496Phase 1
• Endoxifen in Adults With Hormone Receptor Positive Solid TumorsCompletedNCT01273168Phase 1
• Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic LeukemiaWithdrawnNCT01271283Phase 2
• Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal CancerWithdrawnNCT01270438Phase 2
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot StudyTerminatedNCT01265381
• Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerCompletedNCT01264432Phase 1
• MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerCompletedNCT01263145Phase 1
• Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain TumorsCompletedNCT01259479Phase 1
• Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasTerminatedNCT01258868Phase 1
• Environmental and Genetic Determinants of NPCTerminatedNCT01257100
• Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung CancerCompletedNCT01255150
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck CancerCompletedNCT01254617Phase 1
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
• EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid TumorsCompletedNCT01251926Phase 1
• A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research PurposesTerminatedNCT01251913
• BRCA Mutations in LatinasCompletedNCT01251900
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingNCT01251874Phase 1
• RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT01251172Phase 2
• Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01249430Phase 1
• AT13387 in Adults With Refractory Solid TumorsCompletedNCT01246102Phase 1
• Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerCompletedNCT01245205Phase 1
• Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid MalignanciesCompletedNCT01243359Phase 1
• An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and LymphomasCompletedNCT01240577Phase 1
• Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid TumorsCompletedNCT01240538Phase 1
• Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast CancerTerminatedNCT01238133Phase 1
• Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersCompletedNCT01237067Phase 1
• RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell LeukemiaWithdrawnNCT01236586Phase 1
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
• Low-Cost Molecular Cervical Cancer Screening StudyCompletedNCT01231945
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine GliomasCompletedNCT01222754Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid TumorsCompletedNCT01218620Phase 1
• Selumetinib and Cetuximab in Treating Patients With Refractory Solid TumorsCompletedNCT01217450Phase 1
• RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by SurgeryWithdrawnNCT01216787Phase 2
• Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent NeuroblastomaCompletedNCT01208454Phase 1
• RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast CancerTerminatedNCT01208441Phase 1
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility GenesActive, not recruitingNCT01200680
• Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal CancerTerminatedNCT01198535Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsCompletedNCT01198184Phase 1
• Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)CompletedNCT01196520
• Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota AnalysesCompletedNCT01194687
• RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT01193881Phase 1
• RO4929097 Before Surgery in Treating Patients With Pancreatic CancerTerminatedNCT01192763Phase 1
• 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid TumorsCompletedNCT01191216Phase 1
• A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid TumorsWithdrawnNCT01182883Phase 1
• A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid TumorsWithdrawnNCT01176500Phase 1/2
• Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 DeficiencyActive, not recruitingNCT01176006Phase 2
• Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-hour RecallCompletedNCT01164254
• Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian WomenCompletedNCT01160549
• Genetics of Mammographic Appearances and Patterns (The GenMap Study)CompletedNCT01160510
• Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01159301Phase 1
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01154426Phase 1
• RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerTerminatedNCT01149356Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid TumorsCompletedNCT01145456Phase 1
• Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerCompletedNCT01145430Phase 1
• Evaluation of Skin, Colonic, and Oral Microbiome and Effect of Time and Antibiotic Treatment on Organism Diversity at Each SiteCompletedNCT01143571
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01141244Phase 1
• Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
• Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure StudyCompletedNCT01139476
• A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and LymphomasCompletedNCT01132911Phase 1
• Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
• Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic LeukemiaCompletedNCT01132573Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
• Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
• Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaTerminatedNCT01126502Phase 1
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver MetastasesCompletedNCT01120288Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With GliomasWithdrawnNCT01117155
• Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407

← National Cancer Institute (NCI) overview and focus areas